GlassScriptPhysician profile
Sean P Brady
NPI 1356583124
$4,679.03
in general payments reported to CMS, 2019-2025
16 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $237 · 2021: $143 · 2022: $385 · 2023: $1,190 · 2024: $1,315 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,038.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $831.48 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $624.71 | 2019-2025 | |
| Csl Behring | $417.81 | 2022-2024 | Hizentra |
| Genentech USA, INC. | $381.09 | 2019-2024 | Xolair |
| Pfizer INC. | $247.91 | 2023-2024 | |
| Optinose US, INC. | $237.15 | 2023-2024 | |
| Pharming Healthcare, INC. | $202.11 | 2020-2023 | Ruconest |
| Amgen INC. | $131.19 | 2024 | Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Glassia |
| Ars Pharmaceuticals Operations, INC. | $124.89 | 2025 | Neffy |
| Alk-Abello, INC | $119.03 | 2019 | |
| Horizon Therapeutics Plc | $95.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $45.81 | 2024 | Dupixent |
| Genentech, INC. | $35.80 | 2023 | Xolair |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $21.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.